Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure resultsSep 30Weekly roundup, 4 itemsamrecibartcenvacibartUpdated
Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screeningSep 29Trial updateMoleculin Biotech, Inc.
AstraZeneca-linked studies: OlympiaN, ZEAL and CHIO3 post results; two new studies registeredSep 25Weekly roundup, 7 itemsAstraZenecaAZD0120
Novo Nordisk registers Phase 3 trial for denecimig in acquired haemophilia A, plus new Phase 1 studySep 25Weekly roundup, 3 itemsdenecimigNNC0642-1895Updated
Innovent registers Phase II gout trial for IBI3011, Phase I hypertension study for IBI3016Sep 25Weekly roundup, 2 itemsIBI3016Innovent Biologics
University of Alberta registers Phase 4 lemborexant nocturia trial with Eisai as collaboratorSep 25Trial updateEisailemborexant
Merck registers Phase 3 sotatercept HFpEF trial; Terns completes two TERN-701 Phase 1 studiesSep 24Weekly roundup, 3 itemsMerck & Co., Inc.sotatercept-csrk
Novlead registers post-market study of INOwill N200 nitric oxide device for neonatal PPHNSep 24Trial updatenitric oxide
Odense University Hospital registers OPTICARE cardiorenal clinic trial for CKD and heart diseaseSep 23Trial update
CardioVision registers two stepped-wedge trials for TORCH transplant pathways in Latin AmericaSep 23Weekly roundup, 2 items
Aytu reports first full launch quarter for EXXUA, fiscal 2026 resultsSep 22Quarterly updateAytu Biopharma, Incgepirone
Gossamer Bio adds Greg Ciongoli to board and audit committeeSep 16PeopleGossamer Bio, Inc.seralutinib
Roche posts results for lebrikizumab COPD trial; crovalimab pediatric aHUS study nears completionSep 10Weekly roundup, 3 itemsChugai Pharmaceuticalcrovalimab
Roivant details Phase 2 PHocus data for mosliciguat, unveils ongoing Phase 3 PHrontier trialSep 8Clinical readoutRoivant Sciences Ltd.
United Therapeutics discloses share count for $477.6 million ASR deal with CitiSep 8PartnershipUnited Therapeutics
Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial dataSep 4Weekly roundup, 7 itemsEli Lillylasmiditan
AstraZeneca week: Imfinzi label update, ASSURE CLL results posted, four trials registeredSep 3Weekly roundup, 6 itemsacalabrutinibAstraZeneca
FDA grants Fast Track designation to Liquidia's YUTREPIA for SSc-related Raynaud's phenomenonSep 3Regulatory milestoneLiquidia Corptreprostinil
Cytokinetics reports positive ACACIA-HCM results for aficamten in non-obstructive HCMAug 28Clinical readoutaficamtenCytokinetics
FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediatelyAug 28Regulatory decisionbrepocitinibRoivant Sciences Ltd.
iBio reports fiscal 2026 results, cites progress across obesity antibody pipelineAug 28Quarterly updateiBio, Inc.
Lilly registers four new trials: Alzheimer's, cardiovascular, obesity, Crohn's programsAug 27Weekly roundup, 5 itemsclazakizumabEli Lilly
Two new registry studies posted: obesity-linked heart failure and long-term glaucoma surgery outcomeAug 26Weekly roundup, 2 items
Imperial College London completes ACTION hypertension study in Nigeria and Sri LankaAug 25Trial updateRemedium Bio Inc
Gossamer Bio secures up to $250 million private placement tied to seralutinib milestonesAug 21Regulatory decisionGossamer Bio, Inc.seralutinib
AstraZeneca adds fourth trial: Phase 3 AZD6234 in obesity, adjunct to incretinsAug 21Weekly roundup, 4 itemsAstraZenecaAZD0292
Scienture launches REZENOPY, cites patent wins and payer gains in Q2 2026 updateAug 20Quarterly updatenaloxoneScienture Holdings, Inc.
Galectin says FDA aligned on Phase 3 design for belapectin in MASH cirrhosisAug 14Quarterly updatebelapectinGalectin Therapeutics Inc
Quince Therapeutics reports Q2 2026 results after closing Orphai acquisitionAug 14Quarterly updateQuince Therapeutics, Inc.
Siriraj glaucoma survey completes in Bangkok; BASIC-S vascular pilot not yet recruiting in OntarioAug 13Weekly roundup, 2 items
Eledon reports Q2 2026 results, confirms Phase 3 kidney transplant trial on track for late 2026Aug 13Quarterly updateEledon Pharmaceuticalstegoprubart
Gossamer reports Q2 2026 results, reacquires seralutinib rights from ChiesiAug 13Quarterly updateGossamer Bio, Inc.seralutinib
Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal studyAug 12Quarterly updateLiquidia Corptreprostinil
CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertensionAug 11Trial updateCRISPR Therapeutics AGCTX340
Inhibikase reports Q2 2026 results as Phase 3 PAH trial expands across 26 countriesAug 11Quarterly updateInhibikase Therapeutics
Kardigan advances three late-stage cardiovascular trials, reports $660.7M cashAug 11Quarterly updatedanicamtivKardigan
Mineralys reports Q2 2026 results, names new CMO ahead of lorundrostat PDUFA dateAug 11Quarterly updatelorundrostatMineralys Therapeutics
CalciMedica reports Q2 2026 results, advances pulmonary hypertension and pancreatitis programsAug 11Quarterly updateCalciMedica, Inc.
Tenax's TNX-103 misses primary endpoint in Phase 3 LEVEL trial for PH-HFpEFAug 10Clinical readoutTenax Therapeutics, Inc.TNX-103
Veradermics files S-1 to register 16.8 million resale shares from PIPE investors and insidersAug 7FinancingVeradermics, Inc.
Gyre reports Q2 2026 results, advances F351 NDA and Cullgen pipelineAug 7Quarterly updateGyre Therapeutics, Inc.
AstraZeneca: Baxdrostat Phase 3 results posted, Saphnelo label updated, new China lupus trialAug 7Weekly roundup, 5 itemsanifrolumab-fniaAstraZeneca
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vantsAug 6Quarterly updateRoivant Sciences Ltd.
Tectonic completes APEX enrollment for TX45 in PH-HFpEF, IDMC backs continuationAug 6Quarterly updateTectonic Therapeutic
Two new trials registered: TAVI closure device study and aldosterone signaling reviewAug 6Weekly roundup, 2 items
Insmed raises BRINSUPRI guidance and combined peak sales estimate to over $14 billionAug 6Quarterly updatebrensocatibInsmed Incorporated
NewAmsterdam reports positive CHMP opinion for obicetrapib, sets PREVAIL and RUBENS timelinesAug 5Quarterly updateNewAmsterdam Pharma Co N.V.
United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027Aug 5Quarterly updateralinepagtreprostinil
Akebia reports Q2 2026 results, VOICE interim data, and new ebribafusp trialAug 5Quarterly updateAkebia Therapeuticsvadadustat
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updatesAug 5Quarterly updateSarepta Therapeutics, Inc.
MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvalsAug 5Quarterly updatefurosemide injection 80 mg/ 10 mlinsulin human
Galectin's chairman converts $105.8 million in debt into equityAug 4FinancingGalectin Therapeutics Inc
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meetingAug 3Quarterly updateOcular Therapeutix, Inc.
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340
Tenax reports Q2 2026 results, confirms August LEVEL trial data and ESC presentationJul 31Quarterly updateTenax Therapeutics, Inc.
McGill University Health Centre/Research Institute of the McGill University Health Centre updates reJul 31Weekly roundup, 5 itemsRecord notice
AstraZeneca posts Phase III baxdrostat hypertension results; registers new myeloma CAR-T trialJul 30Weekly roundup, 2 itemsAstraZenecaAZD0120
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 resultsJul 30Quarterly updateMadrigal Pharmaceuticals, Inc.resmetirom
HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advancesJul 30Quarterly updateHutchmed
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
MapLight's ML-007C-MA hits primary endpoint, company plans confirmatory pivotal trialJul 27Clinical readoutMapLight TherapeuticsML-007C-MA
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDAJul 27PartnershipGossamer Bio, Inc.seralutinib
NewAmsterdam and Menarini get positive EU CHMP opinion for obicetrapib medicinesJul 24Regulatory milestoneNewAmsterdam Pharma Co N.V.
Scribe Therapeutics prices $128.7 million IPO at $15 per shareJul 24FinancingScribe Therapeutics, Inc.
MannKind raises $50 million in private placement tied to Furoscix ReadyFlow approvalJul 24Financingfurosemide injection 80 mg/ 10 mlMannkind Corporation
China Pharma Holdings prices $5 million registered direct offering at $2.00 per shareJul 23FinancingChina Pharma Holdings, Inc.
FDA grants orphan drug status to Inhibikase's IKT-001 for PAHJul 23Regulatory milestoneIKT-001Inhibikase Therapeutics
India registers CKMS observational registry backed by Sun PharmaceuticalJul 22Trial updateSun Pharmaceutical Industries
Gemelli registers interventional EV trial mapping vascular complications in systemic sclerosisJul 21Trial update
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
University of Rijeka completes pilot trial on mindfulness, forest bathing in hypertensive womenJul 17Trial update
Insmed reports 12-month OLE data for TPIP in pulmonary arterial hypertensionJul 16Clinical readoutInsmed Incorporated
New trial registered for Songling Xuemaikang Capsules in hypertension with insomniaJul 16Trial update
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca
United Therapeutics posts results for terminated Phase 3 ralinepag CPET studyJul 6Trial updateralinepagUnited Therapeutics
Tenax to present Phase 3 LEVEL trial data at ESC Congress 2026, expects topline results in AugustJul 2Clinical readoutTenax Therapeutics, Inc.
Novo Nordisk posts Phase 3 icodec vs. glargine results; registers two observational studiesJul 2Weekly roundup, 3 itemsinsulin icodecNovo Nordisk A/S
Scribe Therapeutics files S-1 for Nasdaq IPO under ticker SCTXJul 2FinancingScribe Therapeutics, Inc.
InflaRx weighs broader EU strategy for vasculitis drugs after Tavneos setbackJun 30Regulatory decisionavacopanInflaRx N.V.
Akebia and USRC halt VOICE trial early after Vafseo beats ESA on safetyJun 30Clinical readoutAkebia Therapeuticsvadadustat
Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody studyJun 30Weekly roundup, 2 itemsfreneslerbartmevonlerbart
FDA approves Viridian's Lumvoa for thyroid eye diseaseJun 26Regulatory decisionveligrotugViridian Therapeutics, Inc.\DE
Sign inSign in